BASIS OF HOXA7 REGULATION OF EPIDERMAL TRANSGLUTAMINASE
Project Number1R03AR045066-01
Contact PI/Project LeaderLA CELLE, PETER T
Awardee OrganizationUNIVERSITY OF ROCHESTER
Description
Abstract Text
DESCRIPTION (from the application):
The ability to control proliferation and differentiation of epidermal
keratinocytes is a major obstacle in wound healing following trauma or
surgery in the treatment of diseases involving abnormal epidermal
differentiation, from carcinomas to psoriasis. The long range goal of this
research is to identify the mechanisms underlying the genetic regulatory
pathways that specify the repertoire of proteins and the associated
morphology characteristic of particular stages of keratinocyte
differentiation. To do this, we must identify the trans-acting factors and
cis-acting elements that regulate differentiation-specific epidermal genes,
such as transglutaminase type 1 (TGM 1). The highly conserved homeobox
(Hox) family of transcription factors can control cell identity and
differentiation, and aberrant regulation can lead deformity or to disease.
Many Hox proteins recognize a common DNA sequence mainly via a small number
of contacts, suggesting that additional mechanisms must underlie their
diverse target specificity. It is now known that cooperative Hox
interaction with cofactors can increase DNA specificity and affinity. We
have identified the HOXA7 cDNA in a differentiating keratinocyte library
through specific interaction with the KD-enhancer that confers
keratinocyte-specific activation to E6/E7 HPV-16 promoter. Sequence
homology indicates that the KD-enhancer is present in the TGM1 5' promoter
region (K3), which contains a Hox DNA recognition core element as well as a
90% identical binding site for heterodimers of Hox and Pbx, the mammalian
homolog of the Drosophila extradenticle. By transient transfection, HOXA7
suppresses transcriptional activity of K3 in neonatal keratinocytes, but
strongly transactivates K3 in the epidermoid carcinoma cell line ME 180. We
propose that HOXA7 differentially regulates the keratinocyte differentiation
marker gone TGM1 in neonatal keratinocytes and ME180, through interaction
with co-factors allowing cell-specific suppression or activation of the same
gone. We will test this hypothesis by 1) determining the cis-acting
elements in the TGM1 upstream regulatory region (K3) important in HOXA7
transactivation in neonatal keratinocytes and ME180 in vivo, and in HOXA7
binding in vitro; 2) identifying the functional domains of HOXA7 necessary
for activation or repression of TGM1 in the two cell types in vivo, and for
K3 binding in vitro; and 3) characterizing nuclear cofactors isolated from
complexes with HOXA7 and K3. This study will elucidate the molecular
mechanisms involved in HOX regulation of keratinocyte proliferation and
differentiation, and in the long term may lead to new methods for
controlling keratinocyte growth in re-epithelialization of wounds, and in
hyperproliferative diseases.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
DUNS Number
041294109
UEI
F27KDXZMF9Y8
Project Start Date
30-September-1997
Project End Date
31-August-2000
Budget Start Date
30-September-1997
Budget End Date
31-August-1998
Project Funding Information for 1997
Total Funding
$79,500
Direct Costs
$50,000
Indirect Costs
$29,500
Year
Funding IC
FY Total Cost by IC
1997
National Institute of Arthritis and Musculoskeletal and Skin Diseases
$79,500
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R03AR045066-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R03AR045066-01
Patents
No Patents information available for 1R03AR045066-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R03AR045066-01
Clinical Studies
No Clinical Studies information available for 1R03AR045066-01
News and More
Related News Releases
No news release information available for 1R03AR045066-01
History
No Historical information available for 1R03AR045066-01
Similar Projects
No Similar Projects information available for 1R03AR045066-01